B44.7 Disseminated aspergillosis

Name of the Condition

• Disseminated aspergillosis

Summary

Disseminated aspergillosis is a severe, systemic fungal infection caused by Aspergillus species. The condition involves widespread invasion of multiple organs beyond the lungs, typically occurring in immunocompromised individuals. Clinical presentations are often severe and may include multi-organ dysfunction, with outcomes dependent on host immunity and timely intervention.

Causes

The infection is caused by Aspergillus species, ubiquitous environmental molds. Spores are inhaled and can disseminate hematogenously or via direct extension in hosts with severely compromised immune systems. Unlike localized forms, disseminated disease involves invasion of distant organs, such as the brain, kidneys, or skin, often following pulmonary or sinus involvement.

Risk Factors

• Severe immunocompromise, including prolonged neutropenia, advanced HIV, or hematologic malignancies.
• Organ transplantation, especially with high-dose immunosuppression.
• Prolonged corticosteroid therapy or other potent immunosuppressive treatments.
• Critical illness requiring intensive care, with associated risk factors like mechanical ventilation.
• Prior invasive aspergillosis or other fungal infections.

Symptoms

• Persistent fever, often unresponsive to antibiotics.
• Respiratory symptoms, such as cough, dyspnea, or hemoptysis.
• Neurologic signs (e.g., headache, altered mental status) if the central nervous system is involved.
• Skin lesions, including nodules or ulcers.
• Abdominal pain, renal dysfunction, or other organ-specific symptoms depending on site of dissemination.

Diagnosis

Diagnosis requires a combination of clinical suspicion, imaging, and microbiologic or histopathologic confirmation. Blood or tissue cultures may identify Aspergillus, though sensitivity can be low. Imaging (e.g., CT, MRI) may reveal multi-organ lesions. Biopsy with histopathology showing fungal hyphae or positive antigen testing (e.g., galactomannan) supports the diagnosis. Distinguishing disseminated disease from localized infection is critical for management.

Treatment Options

Treatment involves antifungal therapy, typically with voriconazole or isavuconazole as first-line agents. Adjunctive therapies, such as surgical debridement of infected tissue, may be necessary. Dose adjustments are often required based on organ function and drug interactions. Supportive care, including managing organ dysfunction, is essential. Duration of therapy depends on clinical response and immune status.

Prognosis and Follow-Up

Prognosis is poor in severely immunocompromised patients, with high mortality rates if not treated promptly. Recovery depends on restoring immune function and controlling the infection. Follow-up includes monitoring for treatment response (e.g., imaging, antigen levels) and managing underlying conditions. Long-term surveillance may be needed to detect recurrence or complications.

Complications

• Multi-organ failure due to widespread infection.
• Respiratory failure from pulmonary involvement.
• Neurologic deficits or stroke from cerebral aspergillosis.
• Skin necrosis or systemic emboli.
• Treatment-related toxicities, such as hepatotoxicity or nephrotoxicity.

Lifestyle & Prevention

• Minimize exposure to high spore environments (e.g., construction sites, moldy areas) for at-risk individuals.
• Use air filtration in healthcare settings to reduce airborne spores.
• Optimize immune status where possible (e.g., managing HIV, reducing immunosuppression).
• Prompt treatment of localized aspergillosis to prevent dissemination.
• Adherence to antifungal prophylaxis in high-risk patients, as directed by healthcare providers.

When to Seek Professional Help

Seek immediate medical attention if experiencing persistent fever, respiratory distress, neurologic changes, or unexplained organ-specific symptoms (e.g., skin lesions, abdominal pain) in immunocompromised states. Early evaluation is critical to prevent progression to severe disease.

Tips for Medical Coders

Code B44.7 is assigned for disseminated aspergillosis, indicating systemic spread beyond the lungs. Documentation should specify the extent of organ involvement (e.g., cerebral, renal, cutaneous) and confirm the diagnosis via clinical, radiologic, or microbiologic findings. Ensure the code is not used for localized or allergic forms of aspergillosis. Verify that underlying immunocompromising conditions are documented if relevant to coding accuracy.